Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) on Tuesday, plunged -3.15% from the previous trading day, before settling in for the closing price of $13.67. Within the past 52 weeks, AMLX’s price has moved between $2.60 and $16.96.
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -78.71%. The company achieved an average annual earnings per share of 65.17%. With a float of $91.15 million, this company’s outstanding shares have now reached $109.77 million.
The extent of productivity of a business whose workforce counts for 123 workers is very important to gauge.
Amylyx Pharmaceuticals Inc (AMLX) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Amylyx Pharmaceuticals Inc is 17.00%, while institutional ownership is 94.74%. The most recent insider transaction that took place on Dec 01 ’25, was worth 94,418. In this transaction Chief Medical Officer of this company sold 6,580 shares at a rate of $14.35, taking the stock ownership to the 175,756 shares. Before that another transaction happened on Dec 01 ’25, when Company’s Officer proposed sale 6,580 for $14.35, making the entire transaction worth $94,419.
Amylyx Pharmaceuticals Inc (AMLX) Performance Highlights and Predictions
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.55 earnings per share (EPS) for the period topping the consensus outlook (set at -0.59) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.33 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 65.17% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 33.77% during the next five years compared to -78.71% drop over the previous five years of trading.
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Trading Performance Indicators
Amylyx Pharmaceuticals Inc (AMLX) is currently performing well based on its current performance indicators. A quick ratio of 13.70 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.80, a number that is poised to hit -0.34 in the next quarter and is forecasted to reach -1.15 in one year’s time.
Technical Analysis of Amylyx Pharmaceuticals Inc (AMLX)
The latest stats from [Amylyx Pharmaceuticals Inc, AMLX] show that its last 5-days average volume of 1.07 million was inferior to 1.3 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 17.49%.
During the past 100 days, Amylyx Pharmaceuticals Inc’s (AMLX) raw stochastic average was set at 60.76%, which indicates a significant increase from 6.77% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.94 in the past 14 days, which was higher than the 0.74 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.94, while its 200-day Moving Average is $8.38. Now, the first resistance to watch is $13.74. This is followed by the second major resistance level at $14.24. The third major resistance level sits at $14.55. If the price goes on to break the first support level at $12.93, it is likely to go to the next support level at $12.62. Assuming the price breaks the second support level, the third support level stands at $12.12.
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Key Stats
Market capitalization of the company is 1.45 billion based on 109,820K outstanding shares. Right now, sales total 87,370 K and income totals -301,740 K. The company made 0 K in profit during its latest quarter, and -34,390 K in sales during its previous quarter.
